Isomorphic Labs announces Novartis collaboration expansion

London, February 18, 2025 – Isomorphic Labs (IsoLabs), an AI-first drug design company, has announced an expansion of its strategic research collaboration with Novartis. This development builds upon the initial partnership established on January 7, 2024.

The expanded agreement includes up to three additional research programs, maintaining the financial terms of the original collaboration. This progression highlights the successful synergy between the two companies over the past year, combining their expertise, data, and technological capabilities to accelerate shared objectives.

"I've long believed that there is no more important application for AI than helping improve human health," said Demis Hassabis, Isomorphic Labs' CEO. "We are delighted to expand and strengthen our deep collaboration with Novartis, and it serves as further evidence of the enormous potential impact AI will have on accelerating drug discovery."

Fiona Marshall, President of Biomedical Research at Novartis, added:

We are thrilled to expand our relationship with Isomorphic Labs. We selected particularly challenging targets for our initial programs with Isomorphic because we appreciate the remarkable potential of their AI-driven capabilities in drug discovery and design. Over the past year, we have witnessed the exploration of new chemical spaces that would be unavailable to probe through traditional methods, and I look forward to continuing our work together on additional difficult targets with the potential to address significant unmet patient needs.